[go: up one dir, main page]

BRPI0516974A - composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis - Google Patents

composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis

Info

Publication number
BRPI0516974A
BRPI0516974A BRPI0516974-7A BRPI0516974A BRPI0516974A BR PI0516974 A BRPI0516974 A BR PI0516974A BR PI0516974 A BRPI0516974 A BR PI0516974A BR PI0516974 A BRPI0516974 A BR PI0516974A
Authority
BR
Brazil
Prior art keywords
staphylococcus epidermidis
inducing
immune response
identification
detection
Prior art date
Application number
BRPI0516974-7A
Other languages
English (en)
Inventor
Bret Richard Sellman
Steven Morris Baker
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0516974A publication Critical patent/BRPI0516974A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

COMPOSIçãO IMUNOGêNICA COMPREENDENDO UM POLIPEPTìDEO; UM MéTODO PARA INDUZIR UMA RESPOSTA IMUNE CONTRA STAPHYLOCOCCUS EPIDERMIDIS; UM MéTODO PARA INDUZIR UMA RESPOSTA IMUNE CONTRA STAPHYLOCOCCUS AUREUS; UM MéTODO PARA A DETECçAO E/OU IDENTIFICAçAO DE STAPHYLOCOCCUS EPIDERMIDIS; UM MéTODO PARA A DETECçAO E/OU IDENTIFICAçAO DE ANTICORPOS PARA STAPHYLOCOCCUS EPIDERMIDIS. A presente invenção refere-se às composições imunogênicas, compreendendo polipeptideos isolados de Staphylococcus epidermidis. A invenção também se refere aos polinucleotídeos que codificam polipeptídeos de Staphylococcus epidermidis e seu uso em composições imunogênicas. Além disso, a invenção se refere a métodos de indução de uma resposta imune em mamíferos contra Staphylococcus epidermidis e Staphylococcus aureus usando composições imunogênicas de polipeptídeos e polinucleotídeos de Staphylococcus epidermidis. A invenção também se refere a métodos para a detecção de Staphylococcus epídermidis numa amostra biológica.
BRPI0516974-7A 2004-10-21 2005-10-19 composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis BRPI0516974A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62078804P 2004-10-21 2004-10-21
PCT/US2005/037746 WO2007001423A2 (en) 2004-10-21 2005-10-19 Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens

Publications (1)

Publication Number Publication Date
BRPI0516974A true BRPI0516974A (pt) 2008-09-30

Family

ID=37595601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516974-7A BRPI0516974A (pt) 2004-10-21 2005-10-19 composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis

Country Status (13)

Country Link
US (3) US8445000B2 (pt)
EP (4) EP2213298A3 (pt)
JP (2) JP2008517918A (pt)
KR (1) KR20070068455A (pt)
CN (1) CN101175508A (pt)
AR (1) AR051826A1 (pt)
AU (1) AU2005333603A1 (pt)
BR (1) BRPI0516974A (pt)
CA (1) CA2583121A1 (pt)
IL (1) IL182546A0 (pt)
TW (1) TW200619228A (pt)
WO (1) WO2007001423A2 (pt)
ZA (1) ZA200703274B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
MX363222B (es) * 2009-04-14 2019-03-15 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
SG176837A1 (en) 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011029034A2 (en) * 2009-09-04 2011-03-10 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of vancomycin resistance genes and vancomycin resistant enterococci
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
EP2729124B1 (en) 2011-07-06 2018-10-24 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
JP2015528457A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
US10328140B2 (en) * 2014-03-26 2019-06-25 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
PE20191320A1 (es) * 2016-10-21 2019-09-24 Socpra Sciences Et Genie Sec Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
IL284077B1 (en) * 2019-01-30 2025-01-01 Fujifilm Electronic Mat Usa Inc Container and method for making it
KR102627009B1 (ko) * 2021-12-17 2024-01-19 (주)메디톡스 피부 유해 세균에 대한 항세균 활성을 갖는 세균 균주, 및 이를 포함하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
ES2155450T5 (es) * 1992-03-19 2008-11-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Anticuerpos opsonicos fuertemente reactivos, que reaccionan a los antigenos comunes de los staphylococcus.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0681483B1 (en) * 1993-01-26 2005-08-24 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Compositions and methods for delivery of genetic material
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0783520T3 (da) * 1994-09-21 2002-03-25 Jackson H M Found Military Med Bredt reaktive opsoniske antistoffer, som er reaktive mod fælles stafylokok-antigener
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
MXPA01002120A (es) * 1998-08-31 2003-03-27 Trinity College Dublin Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa.
AU770333B2 (en) 1998-09-30 2004-02-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutant cholera holotoxin as an adjuvant
WO2001034809A2 (en) 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
ATE451386T1 (de) 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
JP5814494B2 (ja) 2002-11-12 2015-11-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP2351842A1 (en) 2005-03-25 2011-08-03 National Research Council Of Canada Method for isolation of soluble polypeptides

Also Published As

Publication number Publication date
AR051826A1 (es) 2007-02-14
US8445000B2 (en) 2013-05-21
AU2005333603A1 (en) 2007-01-04
EP1802335A2 (en) 2007-07-04
WO2007001423A3 (en) 2007-11-15
CN101175508A (zh) 2008-05-07
ZA200703274B (en) 2008-06-25
US20130209501A1 (en) 2013-08-15
US20070292450A1 (en) 2007-12-20
IL182546A0 (en) 2008-12-29
CA2583121A1 (en) 2007-01-04
EP2298341A3 (en) 2011-07-13
EP2340848A2 (en) 2011-07-06
US20150196629A1 (en) 2015-07-16
EP2213298A3 (en) 2011-07-20
EP2340848A3 (en) 2011-09-14
EP2213298A2 (en) 2010-08-04
EP2298341A2 (en) 2011-03-23
JP2008517918A (ja) 2008-05-29
WO2007001423A2 (en) 2007-01-04
JP2013121981A (ja) 2013-06-20
TW200619228A (en) 2006-06-16
KR20070068455A (ko) 2007-06-29

Similar Documents

Publication Publication Date Title
BRPI0809926B8 (pt) composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
BRPI0516974A (pt) composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
UY26783A1 (es) Antígenos de estreptococo.
CY1118149T1 (el) Πρωτεϊνες και νουκλεϊνικα οξεα απο escherichia coli σχετιζομενο με μηνιγγιτιδα/σηψη
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
BRPI0721003A2 (pt) Polinucleotídeo; vetor; célula recombinante; polipeptídeo; anticorpo; composição; composição preparada por um processo; uso da composição; método para preparar uma composição; método para preparar uma composição de anticorpo; método para induzir uma resposta imune em um mamífero; e método para prevenir ou tratar meningite bacteriana em um mamífero.
Taverna et al. Characterization of cell wall associated proteins of a Staphylococcus aureus isolated from bovine mastitis case by a proteomic approach
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
van Onselen et al. Bacteria do not incorporate β-N-methylamino-l-alanine into their proteins
GT200800132A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
BR112012014801A8 (pt) uso combinado de proteínas cry1ca e cry1fa para controle de resistência a insetos
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
BRPI0508722A (pt) proteìna recombinante, polinucleotìdeo, vetor de expressão e célula hospedeira recombinantes, composição imunogênica, uso de proteìna recombinante, composição de vacina, composição de droga, kit diagnóstico de, ou um kit para imunomonitorar, uma infecção com hpv, método para o diagnóstico in vitro ou para a imunomonitoração de uma infecção com hpv, uso de uma proteìna recombinante, e, processo para a triagem de epìtopos de células t crìticos desconhecidos ou sub-dominantes em um polipeptìdio
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
BRPI0708344B8 (pt) vetores adenovirais quiméricos e composição imunogênica
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112018007154A2 (pt) polipeptídeo de ligação a pd-l1, proteína de fusão ou conjugado, complexo, polinucleotídeo, e composição
Di Martino Bap: a new type of functional amyloid
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
Wang et al. Molecular and biochemical characterization of calmodulin from Echinococcus granulosus
MX2018013372A (es) Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.
BR112017022076A2 (pt) fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
Sassi et al. Identification of Dirofilaria immitis proteins recognized by antibodies from infected dogs
HN2010000718A (es) Proteina m de estreptococo, fragmentos inmunogenicos,acidos nucleicos y metodos de uso.
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A PETICAO NO 20090072588/RJ DE 28.07.09 SEJA ATENDIDA, APRESENTAR PROCURACAO ORIGINAL, OUCOPIA AUTENTICADA, DANDO PODERES PARA DESISTIR DO PEDIDO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020090072588/RJ DE 28.07.09, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISOII DA LPI.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.